Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1978 1
1981 1
1982 1
1985 1
1989 1
1993 1
1995 3
1996 3
1997 3
1998 5
1999 3
2000 3
2001 10
2002 13
2003 20
2004 18
2005 13
2006 19
2007 10
2008 6
2009 7
2010 7
2011 13
2012 8
2013 3
2014 3
2015 4
2016 3
2017 3
2018 1
2021 0
Text availability
Article attribute
Article type
Publication date

Similar articles for PMID: 15579515

178 results
Results by year
Filters applied: . Clear all
Page 1
Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results.
Remuzzi G, Ruggenenti P, Perna A, Dimitrov BD, de Zeeuw D, Hille DA, Shahinfar S, Carides GW, Brenner BM; RENAAL Study Group. Remuzzi G, et al. J Am Soc Nephrol. 2004 Dec;15(12):3117-25. doi: 10.1097/01.ASN.0000146423.71226.0C. J Am Soc Nephrol. 2004. PMID: 15579515 Free article. Clinical Trial.
Losartan reduces the costs of diabetic end-stage renal disease: an Asian perspective.
Seng WK, Hwang SJ, Han DC, Teong CC, Chan J, Burke TA, Carides GW, Choi YJ. Seng WK, et al. Nephrology (Carlton). 2005 Oct;10(5):520-4. doi: 10.1111/j.1440-1797.2005.00472.x. Nephrology (Carlton). 2005. PMID: 16221106 Clinical Trial.
The impact of losartan on the lifetime incidence of ESRD and costs in Mexico.
Arredondo A, Burke TA, Carides GW, Lemus E, Querol J. Arredondo A, et al. Rev Invest Clin. 2005 May-Jun;57(3):399-405. Rev Invest Clin. 2005. PMID: 16187699
Losartan reduces the costs associated with nephropathy and end-stage renal disease from type 2 diabetes: Economic evaluation of the RENAAL study from a Canadian perspective.
Burgess ED, Carides GW, Gerth WC, Marentette MA, Chabot I; Canadian Hypertension Society. Burgess ED, et al. Can J Cardiol. 2004 May 1;20(6):613-8. Can J Cardiol. 2004. PMID: 15152291 Clinical Trial.
Pharmaco-economic consequences of losartan therapy in patients undergoing diabetic end stage renal disease in EU and USA.
de Portu S, Citarella A, Cammarota S, Menditto E, Mantovani LG. de Portu S, et al. Clin Exp Hypertens. 2011;33(3):174-8. doi: 10.3109/10641963.2010.531846. Epub 2011 Apr 5. Clin Exp Hypertens. 2011. PMID: 21466388 Clinical Trial.
Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study.
Bakris GL, Weir MR, Shanifar S, Zhang Z, Douglas J, van Dijk DJ, Brenner BM; RENAAL Study Group. Bakris GL, et al. Arch Intern Med. 2003 Jul 14;163(13):1555-65. doi: 10.1001/archinte.163.13.1555. Arch Intern Med. 2003. PMID: 12860578 Clinical Trial.
Recent advances in management of type 2 diabetes and nephropathy: lessons from the RENAAL study.
Keane WF, Lyle PA; Reduction of Endpoints in NIDDM with the Angiotensin II Receptor Antagonist Losartan study. Keane WF, et al. Am J Kidney Dis. 2003 Mar;41(3 Suppl 1):S22-5. doi: 10.1053/ajkd.2003.50078. Am J Kidney Dis. 2003. PMID: 12612946 Review.
Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluation.
Herman WH, Shahinfar S, Carides GW, Dasbach EJ, Gerth WC, Alexander CM, Cook JR, Keane WF, Brenner BM. Herman WH, et al. Diabetes Care. 2003 Mar;26(3):683-7. doi: 10.2337/diacare.26.3.683. Diabetes Care. 2003. PMID: 12610022 Clinical Trial.
Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.
Eijkelkamp WB, Zhang Z, Remuzzi G, Parving HH, Cooper ME, Keane WF, Shahinfar S, Gleim GW, Weir MR, Brenner BM, de Zeeuw D. Eijkelkamp WB, et al. J Am Soc Nephrol. 2007 May;18(5):1540-6. doi: 10.1681/ASN.2006050445. Epub 2007 Apr 4. J Am Soc Nephrol. 2007. PMID: 17409317 Free article. Clinical Trial.
[Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy].
Parving HH, Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S. Parving HH, et al. Ugeskr Laeger. 2001 Oct 1;163(40):5514-9. Ugeskr Laeger. 2001. PMID: 11601117 Clinical Trial. Danish.
178 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page